Captopril

Routes
Oral (PO)
Half-Life (t½)
PO: 2h
Formula
C9H15NO3S
Molecular Weight
217.29 g/mol
PubChem CID
44093
Aliases
Capoten

Pharmacological Mechanism

First-developed ACE inhibitor — short-acting, sulfhydryl-containing. Faster onset than enalapril (active drug, no prodrug) supports use in hypertensive urgency. Sulfhydryl group may contribute to higher rash + dysgeusia (metallic taste) than newer ACEi.

Half-Life & Elimination Curve (PO: 2h)

100%50%25%12.5%0%0h0×t½2h1×t½4h2×t½6h3×t½8h4×t½10h5×t½0×t½ (0h): 100% remaining (~0.367 mg/L)1×t½ (2h): 50% remaining (~0.183 mg/L)2×t½ (4h): 25% remaining (~91.7 µg/L)3×t½ (6h): 12.5% remaining (~45.8 µg/L)4×t½ (8h): 6.3% remaining (~22.9 µg/L)5×t½ (10h): 3.1% remaining (~11.5 µg/L)
Plasma (PO)t½ Decay (2h)
  • 0×t½0h100% (0.367 mg/L)
  • 1×t½2h50% (0.183 mg/L)
  • 2×t½4h25% (91.7 µg/L)
  • 3×t½6h12.5% (45.8 µg/L)
  • 4×t½8h6.3% (22.9 µg/L)
  • 5×t½10h3.1% (11.5 µg/L)
Elimination t½2h (PO)
Rate Constant (ke)0.347 h⁻¹
Time to Peak (Tmax)1.33h
Est. Peak (Cmax)0.367 mg/L
Clearance (CL)19.4 L/h
97% Washout (5×t½)10h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References